What's hot

View all perspectives
      Agree!
      Liz Volkmann said it straight

      Unsustainable RCTs in ILD trials in #scleroderma

      Why
      Can’t recruit
      ~same pool

      Janet Pope Janetbirdope

      1 year 3 months ago
      Agree! Liz Volkmann said it straight Unsustainable RCTs in ILD trials in #scleroderma Why Can’t recruit ~same pool of early #dcSSc design RCT UNETHICAL a to have a progressing #scleroderma-ILD Pt on failed background #MMF + placebo for 1 yr 🙏🏻 #EULAR2024 @RheumNow @eular_org https://t.co/29oFEazwmM
      I think if we’re worried about JAK inhibitor safety, we need to be doing it right.

      I wrote this for @RheumNow for #EU

      David Liew drdavidliew

      1 year 3 months ago
      I think if we’re worried about JAK inhibitor safety, we need to be doing it right. I wrote this for @RheumNow for #EULAR2024 ahead of my debate against @Janetbirdope, but also drew my inspiration from @RADoctor in @ACR_Journals - a must read: https://t.co/RA6ktQAzqO https://t.co/lltDbtxpAg
      🗓️ Our abstract on psychosocial determinants of health in #RheumatoidArthritis will be presented at #EULAR2024

      ?

      Mrinalini Dey DrMiniDey

      1 year 3 months ago
      🗓️ Our abstract on psychosocial determinants of health in #RheumatoidArthritis will be presented at #EULAR2024 📹 Watch my video on @RheumNow for a sneak preview! 📍 Join me to hear more on #PARE Poster Tour IV, Friday 14th June, 12:00 - 13:00 CEST https://t.co/rDTJVukD6j
      ➡️POS0591 Are there sex differences in risk & outcomes of stroke in patients with #RA?

      📈Stroke risk in RA in

      Mrinalini Dey DrMiniDey

      1 year 3 months ago
      ➡️POS0591 Are there sex differences in risk & outcomes of stroke in patients with #RA? 📈Stroke risk in RA increased compared to general population 🫀Not fully explained by traditional risk factors or AF 📊Stroke-related mortality differs in women vs men @RheumNow #EULAR2024
      POS0592 Increased overall & cause-specific mortality in population-based cohort of people with incident #RA

      Higher

      Mrinalini Dey DrMiniDey

      1 year 3 months ago
      POS0592 Increased overall & cause-specific mortality in population-based cohort of people with incident #RA Higher mortality in RA vs gen pop but this has decreased after 2000 & better 10-year survival Severe causes of mortality incl cardiac higher in RA EULAR2024 @RheumNow
      POS1035 FVC & risk of lung transplant & mortality in #RAILD

      50% pts had FVC % predicted decline in ~6.5yrs

      2/3

      Mrinalini Dey DrMiniDey

      1 year 3 months ago
      POS1035 FVC & risk of lung transplant & mortality in #RAILD 50% pts had FVC % predicted decline in ~6.5yrs 2/3 identified groups more strongly assoc w transplant or ILD-related death than INBUILD definition ➡️marked heterogeneity in ILD progression #EULAR2024 @RheumNow
      #EULAR2024 POS1245 Healthcare Administrative Data in Italy showed despite prevalence of 3.8/10,000, heathcare cost in #S

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 3 months ago
      #EULAR2024 POS1245 Healthcare Administrative Data in Italy showed despite prevalence of 3.8/10,000, heathcare cost in #Sjogren was 3 x higher than the general population due to active disease & comorbidities. Call for better MDT approach in management @RheumNow https://t.co/EevoT4jkqr
      important session worth reading the full recommendations - TNF tick of approval @RheumNow #EULAR2024 https://t.co/ORDocV

      Peter Nash drpnash

      1 year 3 months ago
      important session worth reading the full recommendations - TNF tick of approval @RheumNow #EULAR2024 https://t.co/ORDocVie11
      #EULAR2024 POS1420 A cohort study with 1/3 each with GCA, PMR and GCA+PMR found that at 6mth, 16% of patients had new di

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 3 months ago
      #EULAR2024 POS1420 A cohort study with 1/3 each with GCA, PMR and GCA+PMR found that at 6mth, 16% of patients had new diabetes/diabetes worsened. Worse in GCA+PMR group with the greatest GC accumulation. Call for better GC-sparing strategy @RheumNow https://t.co/ex7u83bVfj
      #EULAR2024 POS0742 A single cohort study showed for non-criteria #APS, cardiac manifestation (valvular dysfunction &

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 3 months ago
      #EULAR2024 POS0742 A single cohort study showed for non-criteria #APS, cardiac manifestation (valvular dysfunction & regurgitation) was more common in Triple Ab+ vs Non-Triple Ab. We should monitor and consider an echocardiogram for this group of patient @RheumNow https://t.co/VxFUSpjaG1
      Active day of learning and discussion with a Round Up from Day 3 of #EULAR2024 with @RheumNow https://t.co/yzLsPNDM5d

      Dr. Antoni Chan synovialjoints

      1 year 3 months ago
      Active day of learning and discussion with a Round Up from Day 3 of #EULAR2024 with @RheumNow https://t.co/yzLsPNDM5d
      #EULAR2024 Please find my short blog on the Impact of Safety Warning Update on the use of JAK-inhibitors @RheumNow

      htt

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 3 months ago
      #EULAR2024 Please find my short blog on the Impact of Safety Warning Update on the use of JAK-inhibitors @RheumNow https://t.co/Z4pujQRQ9h https://t.co/QRUnJInblH
      #EULAR2024 POS0024 Lymphopenia, anemia, & low Plt are assoc with disease activity & damage accrual in #lupus. Po

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 3 months ago
      #EULAR2024 POS0024 Lymphopenia, anemia, & low Plt are assoc with disease activity & damage accrual in #lupus. Post-hoc analysis of RCTs + LTE showed Anifrolumab normalised these Haem parameters vs PBO. May improve fatigue-associated with anaemia @RheumNow https://t.co/GF8aKU0Z5x
      SLE Preview: abolishing refractory with CAR-T and better B-cell therapies

      Despite advancements, some SLE patients rema

      Dr. John Cush RheumNow

      1 year 3 months ago
      SLE Preview: abolishing refractory with CAR-T and better B-cell therapies Despite advancements, some SLE patients remain refractory to belimumab and off-label rituximab, the main B cell-targeted therapies in the last 15 years. https://t.co/778buNUq1C https://t.co/4ub8VbrLb6
      A Puzzling Era in Global Drug Development?
      1 year 3 months ago

      Podcasts

      • EULAR 2024 SLE Topic Panel
      • EULAR 2024 Psoriatic Arthritis Topic Panel
      • EULAR 2024 Rheumatology Roundup

      Catch up on Conference Podcasts

      ×